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Abstract: Objective To investigate the relationship between the polymorphism of glutathione S transferase M1, T1(GSTM1, 
GSTT1) gene and the susceptibility to antituberculosis drug induced hepatotoxicity (ATDH) in patients with tuberculosis. Methods 
GSTM1 and GSTT1 gene polymorphisms in patients with or without liver toxicity after antituberculous treatment were analyzed us-
ing multiple PCR method. Results  In ATDH group and control group, the proportion of GSTM1 gene deletion was 58.0% and 50.7% 
respectively, and the difference was not statistically significant (OR=1.322, 95%CI=0.921~1.878), the frequencies of GSTT1 deletion 
were 46.3% and 49.3%, respectively, and there was no significant difference between them. There was no significant difference in 
frequency of GSTM1 and GSTT1 variation between case group and control group (P> 0.05), and no synergistic effect of those two 
gene polymorphism were detected in the occurrence of antituberculosis drug-induced hepatotoxicity. Conclusion  The polymorphisms 
of GSTM1 and GSTT1 genes may not be associated with the risk of ATDH.
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1. Introduction
Tuberculosis (TB) remains a global major infectious disease, especially in developing countries. World Health Organization (WHO) has declared TB as a 
public health emergency since 1993[1]. 
At present, Standard short-course chemotherapy based 
on isoniazid, rifampicin, pyrazinamide, and ethambutol 
has been accepted by many countries and is the basic 
scheme for the treatment of tuberculosis [2, 3]. A large num-
ber of clinical studies have shown that isoniazid, rifampi-
cin and azininazinamid are to some extent susceptible to 
the occurrence of hepatotoxicity [3-8], especially when the 
above drugs were adminstored together, the incidence and 
severity of hepatotoxicity increased significantly. Antitu-
berculosis drug-induced hepatotoxicity causes substantial 
morbidity and mortality with an incidence ranged from 
2.5% to 34.9% [6,9]. The pathogenesis of antituberculosis 
drug-induced hepatotoxicity is unclear. 
Currently, it is generally considered that the process 
of drug-induced hepatotoxicity is composed of multiple 
steps, including the entry of drugs into the liver tissue, the 
formation of enzyme catalyzed metabolic products, the 
metabolites as immunogens are then combined with en-
dogenous proteins to induce immune damage or directly 
cause hepatocyte intoxication. In these steps, drug metab-
olism enzymes play a significant role in drug detoxifica-
tion and activation, which exert important effect on drug 
efficacy and sensitivity to toxicity[10]. GSTM1 and GSTT1 
are members of the GST family, and they both have de-
toxification functions for exogenous chemicals. Deletion 
homozygote of those two genes could cause the loss of 
enzyme activity [11]. There are reports that [12-18], GSTM1 
and GSTT1 gene polymorphisms are related to the oc-
currence of anti tuberculosis drug hepatotoxicity, but the 
conclusions are not consistent. In this study, a case-control 
study was conducted to explore the association between 
GSTM1 and GSTT1 gene polymorphisms and suscepti-
bility to antituberculosis drug-induced hepatotoxicity in 
Chinese population.
2. Study Objects 
2.1 Study Object
Between May 2010 and March 2016, 600 patients with 
newly diagnosed tuberculosis who met the selection crite-
ria were included. The case group consisted of 300 patients 
with hepatotoxicity after receiving first-line anti-tubercu-
losis treatment (2HRZE/4HR). Hepatic toxicity of anti-tu-
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berculosis drugs is defined as asymptomatic or symptoms 
of hepatitis, such as loss of appetite, nausea, and vomiting 
after taking anti-TB drugs, together with at least one of the 
following conditions, (1) Serum AST and/or ALT is 3 times 
(or > 120 U/L) above the upper limit of normal, (2) In two 
consecutive blood samples, ALP test values is two times 
greater than the upper limit of normal , (3) Any increase in 
ALT, AST, ALP accompanied by progressively elevated 
bilirubin (>2.5 mg/dl). 300 patients with tuberculosis were 
selected as controls. These patients took the same anti-tu-
berculosis drugs but no hepatotoxicity appeared. All en-
rolled subjects must meet the following conditions: At the 
beginning of chemotherapy, liver function is normal and 
there are no other factors that may cause liver damage, 
such as malnutrition, HIV infection, alcohol abuse, viral 
hepatitis, liver disease, cardiac insufficiency, and the use 
other drugs, etc. In the course of treatment, changes in liv-
er function were closely monitored in all subjects.
2.2 Methods
2.2.1 Human Peripheral Blood DNA Extraction
The whole blood sample of the tuberculosis patients men-
tioned above was collected, and a genome-wide extraction 
kit (Tiangen Biotech, Beijing, China) was used to extract 
DNA in blood according to the instructions, and the ex-
tract is immediately stored in a -20°C refrigerator for sub-
sequent use. 
2.2.2 Determination of GSTM1 and GSTT1 Genes
According to the report [13], the GSTM1 and GSTT1 genes 
were simultaneously examined by multiplex PCR and 
β-globin was used as an internal control. The GSTM1 
((Upstream: 5'GAACTCCCTGAAAAGCTAAAGC3', 
Downstream:  5 'CTTGGGCTCAAATATACGGT-
GG3', 219bp), GSTT1 (Downstream: 5' CTTGGGCT-
CAAATATACGGTGG 3', Downstream: 5' TCAC-
CGGATCATGGCCAGCA 3', 459bp), and β-globin 
(Upstream: 5' CAACTTCATCCACGTTCACC 3', Down-
stream: 5' GAAGAGCCAAGGACAGGTAC 3', 68bp) 
gene amplification primers were constructed successively.
 The PCR reaction is a 25 ul amplification system, the 
final concentrations of each substances were as follows: 
0.2mmol/L of each of the 4 dNTPs, 0.3mmol/L primer, 10 
to 100ng DNA template, and 1U Taq DNA polymerase. 
The conditions for PCR were pre-denaturation at 94°C for 
4 minutes, followed by 35 cycles of denaturation at 94°C 
for 40 seconds, annealing at 62°C for 30 seconds, and 
extension at 72°C for 40 seconds, and a final extension at 
72°C for 10 minutes. The PCR products were separated 
by 2.0% agarose gel electrophoresis, and the results were 
observed on a gel imaging and analysis system.
2.3 Genotyping
β-globin was used as an internal control with an amplifi-
cation product showed at 268 bp, no β-globin fragment 
means inefficient amplification.  After amplification of the 
DNA sample by PCR, 219 bp fragments and 459 bp frag-
ments were generated, which were defined as GSTM1(+) 
and GSTT1(+), respectively. No corresponding amplifi-
cation products were considered to be homozygous dele-
tions, namely GSTM1(-) and GSTT1(-).
2.4 Statistical Analysis
Spss 13.0 software, t-test, x2 test and other methods were 
used to analyze the basic parameters of the two groups, 
and x2 test, factorial analysis and other methods were 
used to analyze the electrophoresis results of PCR prod-
ucts. The test level is α=0.05.
3. Results
3.1 Analysis of Basic Parameters
There was no significant difference in gender and age 
between the patient group and the control group. The 
values of ALT, AST, DBIL, TBIL, GGT and ALP before 
treatment were within the normal range. The comparison 
of serum ALT, AST, DBIL, TBIL, GGT and ALP between 
the two groups before and after treatment are shown in 
Table 1.
Table 1. Comparison of Patients' Parameters in Case Group and 
Control Group
case group control group P
Gender(M/F ) 174/126 160/140 0.287
Age(years) 37.19±18.193 36.41±18.661 0.167
Before
ALT(U/L) 18.64±10.887 14.21± 6.546
AST(U/L) 23.16±9.017 19.43±6.326
DBIL(μmol/L) 5.628±7.012 4.325±3.246
TBIL(μmol/L) 12.756±7.687 10.294±7.426
GGT(U/L) 24.25±5.147 26.12±4.923
ALP(U/L) 64.52±20.156 58.43±18.915
After
ALT(U/L) 196.946±208.431 18.488±9.058
AST(U/L) 180.047±268.417 20.475±6.721
DBIL(μmol/L) 11.231±20.754 4.513±2.013
TBIL(μmol/L) 23.742±30.457 11.126±5.621
GGT(U/L) 46.41±12.156 27.13±9.867
ALP(U/L) 100.45±38.426 64.87±20.124
3.2 PCR Amplification
If GSTM1 and GSTT1 genes are both positive (labeled as 
GSTM1(+)/GSTT1(+)), the DNA samples will produce 
219bp, 459bp and 268bp fragments after PCR amplifica-
tion. Accordingly, GSTM1(+)/GSTT1(-) genotype showed 
two fragments of 219bp and 268bp, GSTM1(+)/GSTT1(-
) genotype has two fragments of 459bp and 268bp, while 
GSTM1(-)/GSTT1(-) genotype only showed 268bp frag-
ments, as showed in Figure 1. 
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3.3 Relationship between GSTM1 and GSTT1 
Genotypes and Susceptibility to Antituberculosis 
Drug-induced Hepatotoxicity
In the case group and the control group, 
the GSTM1 deletion genotypes accounted 
for 58.0% and 50.7%, respectively, the 
difference was not statistically significant 
(P>0.05), but the OR value of drug-in-
duced hepatic impairment in GSTM1 deletion genotypes 
subjects is 1.32 (95% CI: 0.921 to 1.878, P>0.05), and 
was higher than normal controls. The GSTT1 deletion 
genotype accounted for 46.3% and 49.3% in these two 
groups, respectively, and the OR value was similar be-
tween the two groups (P>0.05). The results are shown in 
Table 2.
3.4 Joint analysis of GSTM1 and GSTT1 genotypes
The phenotypes of GSTM1 and GSTT1 genes were 
combined to analyze their relationship with ADTH. 
GSTM1(+)/GSTT1(+) subjects were considered as refer-
ence group. The results showed that there was no signif-
icant difference in the frequency of GSTM1(-)/GSTT1(-
) genotype between the case group and the control group 
(p>0.05). Compared with patients with a GSTM1-deleted 
genotype (OR: 1.212, 95% CI: 0.762 to 1.967, P>0.05)
or GSTT1-deficient genotype(OR: 0.736, 95% CI: 0.462 
to 1.243, P>0.05), there was no significant increase in 
the risk factor for anti-tuberculous drug-induced hepatic 
impairment in the GSTM1(-)/GSTT1(-) genotype (OR: 
1.153, 95% CI: 0.722 to 1.872, P>0.05). The results are 
shown in Table 3.
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
459bp
268bp
219bp
Figure 1. Agarose Gel Electrophoresis after PCR Amplification 
of GSTM1 and GSTT1
Table 2. Relationship between GSTM1 and GSTT1 Gene and 
ADTH in 600 Tuberculosis Patients
Table 3. Joint Analysis of GSTM1 and GSTT1 Genotypes with 
ATDH in 600 Tuberculosis Patients
4. Discussion
Glutathione S-transferase (GST) is an important phase 
II detoxification enzyme, it catalyzes the binding of the 
intermediate metabolites of the foreign compounds with 
reduced glutathione, and the resulting reduced glutathi-
one conjugate is less toxic and easily excreted. There-
fore, they have an important role in protecting cells from 
chemical attacks [19]. GSTM1 and GSTT1 are members 
of the GST family, both of which have detoxifying func-
tions for exogenous chemicals, and its deletion homozy-
gote could cause the loss of their corresponding enzyme 
activity [11]. 
A number of studies have been conducted to explore 
the relationship between GSTM1 and GSTT1 gene poly-
morphisms and anti-tuberculous drug-induced hepato-
toxicity. In an Indian study of genetic polymorphisms 
of GSTM1 and GSTT1 in 33 patients with liver toxicity 
associated with antituberculosis drug and 33 treated TB 
patients without hepatotoxicity, Bidyut Roy et al[12] found 
that the risk for anti-tuberculosis drug-induced hepatic 
impairment in the GSTM1 deletion genotype was 2.13, 
so it might predicted the occurrence of hepatotoxicity 
against TB drugs. However, the difference in GSTT1 
gene mutation and hepatotoxicity was not statistically 
significant between cases and controls. The above con-
clusion was supported by other researches, such as Yi-
Shin Huang et al[13], but other studies have different 
conclusions. Virginia Leiro et al[14] conducted a retro-
spective study of 1,200 patients with active pulmonary 
tuberculosis in Spain from 1998 to 2006, they found that 
the GSTT1 homozygote deletion genotype was a risk 
factor for the development of hepatotoxicity of antituber-
culosis drugs (odds ratio 2.60), whereas GSTM1 was not 
significantly associated with hepatotoxicity. Furthermore, 
patients with both GSTM1 and GSTT1 deletion also had 
a lower risk factor for anti-tuberculosis drug-induced 
hepatic impairment than those with 
a single GSTT1 deletion. However, 
Studies by Sang-Heon Kim et al[15] in 
a Korean population showed that the 
GSTT1 and GSTM1 deletion variant 
genotypes were not associated with 
GSTM1 GSTM1
+ - + -
case group 126 174 161 139
control group 148 152 152 148
OR(95%CI) 0.724(0.508~1.028)
1.322
(0.921~1.878)
1.157
(0.799~1.560)
0.866
(0.618~1.217)
p 0.071 0.462
χ2 3.251 0.541
genotype case 
group
control 
group
OR(95%CI) p χ2GSTM1 GSTT1
+ + 72 74 1
+ - 53 74 0.736(0.462~1.243) 0.210 1.573
- + 92 78 1.212(0.762~1.967) 0.394 0.726
- - 83 74 1.153(0.722~1.872) 0.537 0.382
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the occurrence of anti-tuberculosis drug-induced hepato-
toxicity, this conclusion were supported by Chatterjee S 
et al [20].
The results of this study show that the GSTM1 and 
GSTT1 gene polymorphisms are not related to the sus-
ceptibility of anti-TB drugs associated liver toxicity. The 
reason for the inconsistency between the findings of this 
study and various reports may be that there are large dif-
ferences in genes from different regions and ethnicities, 
coupled with the small sample size of predecessors and 
differences in diagnostic criteria for hepatotoxicity. More-
over, anti-tuberculous drug hepatotoxicity is a multi-fac-
tor, multi-gene-related disease. When selecting cases and 
controls, the influence of various factors can easily be 
offset by each other, resulting in false negatives. There-
fore, prospective randomized trials with large sample size 
and multivariate analysis are still needed to confirm the 
relationship between GSTM1 and GSTT1 and hepatotox-
icity.
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